Insider Trading Activity Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) – EVP Sold 437 shares of Stock

Insider Trading Activity For Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM)

Story continues below

Alan K. Smith , EVP of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) reportedly Sold 437 shares of the company’s stock at an average price of 11.85 for a total transaction amount of $5,178.45 SEC Form

Insider Trading History For Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM)

  • On 6/16/2015 David M Spencer, Insider, sold 20,000 with an average share price of $22.96 per share and the total transaction amounting to $459,200.00.View SEC Filing
  • On 7/15/2015 Kevin M Slawin, CTO, sold 6,000 with an average share price of $20.00 per share and the total transaction amounting to $120,000.00.View SEC Filing
  • On 9/1/2015 Thomas J Farrell, CEO, sold 2,500 with an average share price of $16.78 per share and the total transaction amounting to $41,950.00.View SEC Filing
  • On 9/11/2015 David M Spencer, Insider, sold 5,000 with an average share price of $19.00 per share and the total transaction amounting to $95,000.00.View SEC Filing
  • On 10/1/2015 Thomas J Farrell, CEO, sold 2,500 with an average share price of $14.58 per share and the total transaction amounting to $36,450.00.View SEC Filing
  • On 11/2/2015 Ken Moseley, VP, sold 15,000 with an average share price of $13.00 per share and the total transaction amounting to $195,000.00.View SEC Filing
  • On 11/24/2015 Alan A Musso, CFO, sold 29,300 with an average share price of $22.34 per share and the total transaction amounting to $654,562.00.View SEC Filing
  • Analyst Ratings For Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM)
    These are 7 Buy Ratings .
    The current consensus rating for Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) is Buy (Score: 3.00) with a consensus target price of $28.43 , a potential (136.90% upside)

    Analyst Ratings History For Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM)

    • On 9/11/2015 Guggenheim Upgraded rating Neutral to Buy with a price target of $38.00
    • On 6/2/2016 SunTrust Banks, Inc. Initiated Coverage of rating Buy with a price target of $20.00
    • On 8/9/2016 Citigroup Inc. Upgraded rating Neutral to Buy with a price target of $24.00
    • On 8/9/2016 Piper Jaffray Companies Reiterated Rating Overweight with a price target of $25.00 to $31.00
    • On 5/9/2017 Jefferies Group LLC Lower Price Target of rating Buy with a price target of $19.00 to $18.00
    • On 6/24/2017 Ladenburg Thalmann Financial Services Set Price Target of rating Buy with a price target of $31.00
    • On 6/26/2017 Cantor Fitzgerald Reiterated Rating Overweight with a price target of $35.00

    Recent Trading Activity for Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM)
    Shares of Bellicum Pharmaceuticals, Inc. closed the previous trading session at 12.00 down -0.18 -1.48% with 309,781 shares trading hands.

    An ad to help with our costs